Illumina (NASDAQ:ILMN) Issues FY 2025 Earnings Guidance

Illumina (NASDAQ:ILMN) updated its FY 2025 earnings guidance on Monday. The company provided EPS guidance of 4.500-4.500 for the period, compared to the consensus EPS estimate of 4.510. The company issued revenue guidance of -. Illumina also updated its FY25 guidance to $4.50 EPS.

Illumina Trading Down 1.7 %

ILMN opened at $84.52 on Wednesday. The business has a 50 day simple moving average of $116.45 and a two-hundred day simple moving average of $130.84. The firm has a market capitalization of $13.39 billion, a price-to-earnings ratio of -11.01, a PEG ratio of 1.60 and a beta of 1.17. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. Illumina has a one year low of $80.18 and a one year high of $156.66.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Analysts predict that Illumina will post 4.51 EPS for the current year.

Analyst Ratings Changes

A number of research firms have recently commented on ILMN. TD Cowen cut Illumina from a “buy” rating to a “hold” rating and cut their target price for the stock from $177.00 to $140.00 in a research note on Friday, February 7th. Robert W. Baird cut their price target on shares of Illumina from $127.00 to $90.00 and set a “neutral” rating on the stock in a report on Wednesday, March 5th. Morgan Stanley cut their target price on Illumina from $150.00 to $136.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 11th. Stephens reaffirmed an “overweight” rating and set a $156.00 price objective on shares of Illumina in a research report on Tuesday. Finally, Piper Sandler raised their target price on shares of Illumina from $185.00 to $190.00 and gave the stock an “overweight” rating in a report on Monday, February 10th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Illumina presently has a consensus rating of “Moderate Buy” and an average price target of $146.85.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.